We investigated the pattern of rash , diarrhea , and hepatic adverse events ( AEs ) secondary to lapatinib and their association with age and pathologic complete response ( pCR ) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation ( NeoALLTO ) phase III trial .